High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.

Cooper, Curtis; Klein, Marina; Walmsley, Sharon; Haase, David; MacKinnon-Cameron, Donna; Marty, Kimberley; Li, Yan; Smith, Bruce; Halperin, Scott; Law, Barb; Scheifele, David

Cooper, Curtis; Klein, Marina; Walmsley, Sharon; Haase, David; MacKinnon-Cameron, Donna; Marty, Kimberley; Li, Yan; Smith, Bruce; Halperin, Scott; Law, Barb; Scheifele, David.

Affiliation

Cooper C; The Ottawa Hospital Division of Infectious Diseases, University of Ottawa, Ottawa, Canada. ccooper@ottawahospital.on.ca

HIV Clin Trials ; 13(1): 23-32, 2012.

Article in En | MEDLINE | ID: mdl-22306585

Subject(s)

Immunization, Secondary; Influenza A Virus, H1N1 Subtype/immunology; Influenza Vaccines/immunology; Pandemics; Adult; CD4 Lymphocyte Count; Female; Hemagglutination Inhibition Tests; Humans; Influenza Vaccines/adverse effects; Male; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Immunization, Secondary / Influenza A Virus, H1N1 Subtype / Pandemics Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: HIV Clin Trials Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) / TERAPEUTICA Year: 2012 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google